Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**LOYON** is a topical dimethicone-based medical device developed and manufactured by G. Pohl-Boskamp for removal of adherent scale in scalp psoriasis. The solution contains dimethicone and dicaprylyl carbonate and acts through a non-pharmacological physical mechanism: it penetrates beneath scales, reduces their adherence to the underlying skin, and facilitates gentle lifting and removal. It is not a conventional salicylic acid or urea keratolytic and has no intended molecular target or pharmacological action. The product was evaluated as Loion in a randomized, active-controlled, observer-blinded Phase 2 study in chronic psoriasis capitis. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01914627))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LOYON.